Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura
NCT07310342 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53
Last updated 2025-12-30
Summary
Patients with chronic immune thrombocytopenic purpura (ITP) live with an anxiety-inducing risk of haemorrhage that is unpredictable over several months or years.
They also rate fatigue as one of the most frequent (48%) and most severe (73%) disabling symptoms, which contributes to a reduced quality of life \[Cooper, 2021\].
In this autoimmune disease targeting platelets, fatigue could be mediated by platelet and immunological abnormalities, and/or promoted by psychobehavioural determinants that are poorly understood in this chronic disease.
Since 1980, the World Health Organisation has stated that functional capacity assessments best reflect the impact of chronic diseases on quality of life, with fatigue playing an important role. The association between fatigue and aerobic physical capacity, determined by maximum oxygen consumption (VO2max), has been demonstrated in several pathologies. It is often associated with the vicious circle of deconditioning, where the impact of the disease on cardiac, muscular and respiratory functions is intertwined with inactive or sedentary behaviours.
At the end of this vicious circle, adults have been shown to have an increased cardiovascular risk and a high prevalence of anxiety and depression syndromes.
VO2max measured by cardiopulmonary exercise testing (CPET) is increasingly used in monitoring, as recommended by the French Society of Cardiology \[Marcadet, 2018;Marcadet, 2019\]. Our team (Amedro et al.) has set up a research programme on aerobic physical capacity and deconditioning to exercise in chronic childhood diseases and has just published the reference values for exercise tests in healthy paediatric populations, enabling the interpretation of VO2max results in sick children \[Gavotto,2023\].
However, it has been demonstrated that the VO₂ plateau is not predominantly reached in healthy adults and is rarely reached (\<25%) in healthy children. \[Armstrong, 1996 ; Åstrand, 1952 ; Rowland, 1992\].
Thus, the highest oxygen consumption measurement (VO2pic) is often used instead of VO2max to define aerobic capacity. We will therefore use the concepts of VO2max and VO2pic in this study.
The first population studied by our team was children with congenital heart disease, who showed a significant reduction in their VO2max \[Amedro, 2018\]. Based on these results, a functional rehabilitation programme (QUALIREHAB) was set up and evaluated in a randomised controlled clinical trial \[Amedro, 2019\] . The data demonstrate its positive impact not only on VO2max, but also on quality of life. Aerobic physical capacity was assessed in chronic paediatric diseases without direct cardiac involvement.
We have also shown that VO2max declines more rapidly over time in children, adolescents and young adults who have survived childhood cancer \[Gavotto, 2023\] or in children with asthma \[Moreau, 2023\].
To date, no prospective controlled studies have reported on the level of aerobic physical capacity in children, adolescents and young adults with cITP.
We therefore hypothesise that fatigue in patients monitored for cITP could be correlated with a decrease in their aerobic physical capacity, causing these patients to enter a 'vicious cycle of deconditioning'. If this hypothesis is verified, an exercise rehabilitation programme could have a positive impact on quality of life, physical health and mental health
Conditions
- Immune Thrombocytopenic Purpura
Interventions
- OTHER
-
IPT-CPET
Patients with ITP will undergo standard care, medical examination, cardiopulmonary exercise test (CPET), muscular strength and physical activity tests, and validated questionnaires of health-related and disease-related quality of life, mental health, and physical activity
Sponsors & Collaborators
-
University Hospital, Bordeaux
lead OTHER
Principal Investigators
-
Pascal AMEDRO, MD,PhD · University Hospital, Bordeaux
-
Nathalie ALADJIDI, MD · University Hospital, Bordeaux
-
Marion AUDIE, MD · University Hospital, Bordeaux
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 8 Years
- Max Age
- 25 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-15
- Primary Completion
- 2026-12-15
- Completion
- 2026-12-22
Countries
- France
Study Locations
More Related Trials
-
Lymphocyte Counts in Immune Thrombocytopenic Purpura
NCT03244410 ·Status: UNKNOWN
-
A Prospective Study on the Long-Term Vascular Burden in Thrombotic Thrombocytopenic Purpura Patients
NCT03187652 ·Status: RECRUITING
-
Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)
NCT06665308 ·Status: COMPLETED
-
Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura
NCT04056507 ·Status: COMPLETED
-
NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults
NCT01172015 ·Status: COMPLETED ·Phase: NA
-
Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura
NCT01571349 ·Status: COMPLETED
-
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582 ·Status: RECRUITING
-
Longitudinal Observational Study on Immune Thrombocytopenia
NCT07068425 ·Status: NOT_YET_RECRUITING
-
Evaluation of HRQoL in Adult With Immune Thrombocytopenia in China
NCT03324087 ·Status: UNKNOWN
-
Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients
NCT06979765 ·Status: RECRUITING ·Phase: NA
-
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
NCT01101295 ·Status: UNKNOWN
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
NCT06817395 ·Status: RECRUITING
-
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748 ·Status: RECRUITING ·Phase: PHASE1
-
Bleeding Prediction in Thrombocytopenia
NCT02306044 ·Status: COMPLETED
-
The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)
NCT00937131 ·Status: COMPLETED ·Phase: PHASE2
-
Research of Predictive Factors to Immune Thrombopenic Purpura
NCT01648556 ·Status: COMPLETED ·Phase: NA
-
Diagnostic of Chronic Thrombocytopenia
NCT04071496 ·Status: COMPLETED
-
Observatory of Immunological Thrombopenic Purpura in the Brest Region
NCT06556888 ·Status: RECRUITING
-
Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00454857 ·Status: COMPLETED
-
Immune Markers in Pediatric ITP on Second Line Therapy
NCT06093529 ·Status: NOT_YET_RECRUITING
-
Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
NCT00168038 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP
NCT00571467 ·Status: TERMINATED ·Phase: PHASE1
-
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439 ·Status: UNKNOWN
-
Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center
NCT07205861 ·Status: RECRUITING
-
Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura
NCT04311593 ·Status: UNKNOWN